Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.05%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.18 per share when it actually produced earnings of $3.34, delivering a surprise of 5.03%.Over the last four quarters, t ...

cencora Cencora, Inc. Fourth Quarter Fiscal 2024 Earnings Call November 6, 2024 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," ...

Revenue and Earnings - Revenue for the fourth quarter of fiscal 2024 was $79.1 billion, a 14.7% year-over-year increase, with U.S. Healthcare Solutions revenue increasing by 15.7% and International Healthcare Solutions revenue increasing by 5.5%[4][19][20] - For fiscal year 2024, revenue reached $294.0 billion, reflecting a 12.1% year-over-year increase, while GAAP diluted EPS decreased to $7.53 from $8.53 in the prior fiscal year[21][22] - Adjusted diluted EPS for the fourth quarter was $3.34, a 16.8% increase compared to $2.86 in the previous fiscal year fourth quarter[16] - Total revenue for the fiscal year ended September 30, 2024, was $293,958,599, representing a 12.1% increase from the previous year[37] - U.S. Healthcare Solutions revenue reached $265,339,427, a 13.0% increase from $234,759,218 year-over-year[51] - International Healthcare Solutions revenue grew by 4.4% to $28,627,542, compared to $27,418,679 in the prior year[51] Operating Income and Expenses - Adjusted operating income for the fourth quarter was $851.1 million, a 6.3% increase compared to the same period in the prior fiscal year[14] - Operating expenses in the fourth quarter increased by 33.2% to $2.4 billion, primarily due to a $418 million goodwill impairment charge related to PharmaLex[6][21] - U.S. Healthcare Solutions segment operating income was $697.4 million, up 10.2% year-over-year, while International Healthcare Solutions segment operating income decreased by 8.6% to $153.7 million[19][20] - Operating income for fiscal 2024 was $3.6 billion, with a negative impact from foreign currency translation of $38.8 million, resulting in constant currency operating income of $3.7 billion[67] - The company achieved an operating income of $2,175,249 for the fiscal year, down 7.1% from $2,340,731 in the previous year[52] Cash Flow and Capital Expenditures - Adjusted free cash flow for the fiscal year ended September 30, 2024, was $3,064.3 million, consisting of net cash from operating activities of $3,484.7 million minus capital expenditures of $487.2 million[66] - Net cash provided by operating activities was $3,484,685 thousand for the fiscal year ended September 2024, down from $3,911,334 thousand in the previous year, a decrease of 10.9%[54] - The company reported capital expenditures of $487,173 thousand, an increase from $458,359 thousand in the previous year, indicating a rise of 6.1%[54] - Net cash used in investing activities was $618,096 thousand, significantly lower than $2,602,465 thousand in the previous year, showing a decrease of 76.3%[54] Guidance and Future Projections - Cencora's fiscal year 2025 financial guidance includes adjusted operating income growth of 5% to 6.5% and adjusted diluted EPS growth of 8% to 10%[27] - Expected revenue growth for fiscal year 2025 is projected to be in the range of 7% to 9%[27] - Adjusted diluted earnings per share is anticipated to be between $14.80 and $15.10[27] - Cencora's fiscal 2025 guidance does not currently include the impact of the RCA acquisition, which will be incorporated after the transaction closes[29] - The company provided non-GAAP fiscal year 2025 guidance for diluted earnings per share, operating income, effective income tax rate, and free cash flow, excluding significant items outside its control[68] Tax and Impairment Charges - The effective tax rate for the fourth quarter was 94.0%, significantly higher than the prior year quarter's 21.8%, primarily due to the PharmaLex goodwill impairment[9][21] - For the fiscal year ended September 30, 2024, the company reported a goodwill impairment charge of $418 million related to PharmaLex[39] - The fiscal year ended September 30, 2024, includes $263.1 million in litigation accruals, partially offset by a $92.2 million reduction in opioid settlement accruals[38] Acquisitions and Strategic Initiatives - Cencora announced the acquisition of Retina Consultants of America, enhancing its specialty healthcare capabilities[2][24] - The company anticipates continued market expansion and product development as part of its strategic initiatives moving forward[42] Assets and Liabilities - Total assets increased to $67,101,667 thousand as of September 2024, up from $62,558,746 thousand in September 2023, representing a growth of approximately 8.7%[53] - Total current liabilities increased to $54,277,053 thousand, up from $48,831,198 thousand, reflecting a rise of approximately 11.1%[53] - Long-term debt decreased to $3,811,745 thousand from $4,146,113 thousand, a reduction of approximately 8.1%[53] - Total equity increased to $786,742 thousand as of September 2024, compared to $666,287 thousand in September 2023, reflecting a growth of approximately 18.1%[53] Other Financial Metrics - Diluted weighted average shares outstanding for the fourth quarter were 198.1 million, a decrease of 2.6% compared to the prior fiscal year fourth quarter due to share repurchases[10][17] - The company reported a gain of $40.7 million from the divestiture of non-core businesses in the fiscal year ended September 30, 2023[39] - The company incurred $227,070 thousand in litigation and opioid-related expenses for the fiscal year ended September 30, 2024[45] - The company faced a goodwill impairment of $418,000 during the fiscal year, which was not present in the previous year[52] - Cash and cash equivalents rose to $3,132,648 thousand in September 2024, compared to $2,592,051 thousand in September 2023, marking an increase of 20.9%[55] - The company’s cash, cash equivalents, and restricted cash at the end of the fiscal year totaled $3,297,880 thousand, up from $2,752,889 thousand, an increase of 19.8%[55]

Cencora (COR) is slated to report fiscal fourth-quarter 2024 results on Nov. 06, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 5.03%. COR’s earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.59%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $77.68 billion, up 12.7% compared with the prior-year quarter. The consensus ...

Analysts on Wall Street project that Cencora (COR) will announce quarterly earnings of $3.21 per share in its forthcoming report, representing an increase of 12.2% year over year. Revenues are projected to reach $77.68 billion, increasing 12.7% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this time ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Cencora (COR) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than exp ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing dr ...

Cencora (COR) shares soared 3.7% in the last trading session to close at $233.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks. Cencora recorded a strong price rise driven by investors' optimism surrounding the company's upcoming earnings release, scheduled on Nov. 6, 2024. The Zacks Consensus Estimate for the fiscal fourth quarter suggests a revenue growth of 12.7% and earnings growth of 12. ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry. This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 4.57%. For the most recent quarter, Cencora was expected to post earnings of $ ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry's 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve ...